Fundraising Fox

Crossbow Therapeutics

Cambridge, US · Founded 2021 · Delaware corporation · 4 known investors

crossbowtx.com ↗

Crossbow Therapeutics develops TCR-mimetic antibody therapies designed to target cancer antigens by mimicking T-cell receptors, with a focus on treating solid tumors and hematologic malignancies. The company creates next-generation T-cell engagers incorporating its proprietary T-Bolt™ molecules to enhance therapeutic potency and manufacturability.

AI & Machine LearningBiotechMedical Devicesin /crossbow-therapeutics-inc

Founders & leadership

AN
Alexander NolteinExecutive Officer
AC
Alexandra CantleyinDirector
DW
Dmitri WiederschaininExecutive Officer
SA
Sakae AsanumainDirector
CBCharles Baum
Charles BauminDirector
IM
Irena MelnikovainDirector
AL
Alon LazarusDirector
GP
Geraldine PaulusinExecutive Officer
BM
Briggs MorrisoninExecutive Officer, Director, Promoter
TF
Todd FoleyinDirector

Investors · 4

MPM BioImpactBoston · $1M – $15Mvia Todd Foley · board
MPM Capital
Pfizer Venture Investments$5M – $20M
Polaris PartnersreportedBoston · $500K – $5Mvia Alexandra Cantley · board

Reported raises · per SEC filings

Form D private placements
▶$30.3MraisedSep 2025 · 17 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Alexander NolteExecutive Officer
  • Alexandra CantleyDirector
  • Dmitri WiederschainExecutive Officer
  • Sakae AsanumaDirector
  • Charles BaumDirector
  • Briggs MorrisonExecutive Officer, Director, Promoter
  • Irena MelnikovaDirector
  • Alon LazarusDirector
  • Todd FoleyDirector
Offering amount
$80M
Amount sold
$30.3M
First sale
Sep 2025
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗
▶$37.6MraisedApr 2023 · 15 investors · Biotechnology
Rule 506(b)
Officers, directors & promoters on the filing
  • Irena MelnikovaDirector
  • Todd FoleyDirector
  • Briggs MorrisonExecutive Officer, Director
  • Alexandra CantleyDirector
  • Geraldine PaulusExecutive Officer
Offering amount
$80M
Amount sold
$37.6M
First sale
Mar 2023
Incorporated
Corporation, Delaware, 2021
Federal exemptions
06b
Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

In the news